MetaCap

Aligos Therapeutics (ALGS) vs Intensity Therapeutics (INTS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Intensity Therapeutics (INTS) has outperformed Aligos Therapeutics (ALGS) over the past year, losing 75.7% versus a loss of 86.8%. Intensity Therapeutics is the larger company by market cap ($8.2 million vs $7.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALGS-86.75%INTS-75.69%
+51%-21%-93%
Nov 21, 20251 yearNov 20, 2026
ALGS-94.97%INTS-98.34%
+88%-10%-107%
Jun 26, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALGS versus INTS key metrics
MetricALGSINTS
Share price$1.22$2.48
Market cap$7.62M$8.19M
1-day change-2.40%-2.36%
YTD return-86.91%-75.80%
1-year return-86.75%-75.69%
5-year return-99.70%—
EPS (TTM)$-6.46$-3.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.19M—
Revenue growth (YoY)-39.46%—
Net income (latest FY)$-24.19M$-11.61M
Operating margin-4024.93%—
Net margin-1106.72%—
52-week high$13.69$15.00
52-week low$1.18$2.28
Distance from 52-week high-91.09%-83.47%
Analyst consensusnonenone
Avg. price target upside+4193.44%+679.44%
Average volume57.37K22.48K
Shares outstanding5.45M3.30M
Employees825
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INTS has outperformed ALGS by 11.1 percentage points over the past year.

About Aligos Therapeutics

ALGS stock →

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees

About Intensity Therapeutics

INTS stock →

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees

ALGS vs INTS FAQ

Which is bigger, Aligos Therapeutics or Intensity Therapeutics?

Intensity Therapeutics (INTS) is larger, with a market capitalization of $8.19M compared with $7.62M for Aligos Therapeutics (ALGS).

Which stock has performed better over the past year, ALGS or INTS?

INTS returned -75.69% over the past 12 months, compared with -86.75% for ALGS (price return, excluding dividends). Past performance does not predict future results.

Are Aligos Therapeutics and Intensity Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons